Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1980 3
1981 7
1982 9
1983 16
1984 13
1985 13
1986 18
1987 14
1988 11
1989 18
1990 25
1991 42
1992 38
1993 28
1994 61
1995 67
1996 64
1997 74
1998 67
1999 83
2000 75
2001 84
2002 102
2003 121
2004 141
2005 178
2006 175
2007 161
2008 238
2009 247
2010 262
2011 288
2012 329
2013 357
2014 361
2015 404
2016 435
2017 459
2018 498
2019 623
2020 610
2021 620
2022 617
2023 617
2024 240

Text availability

Article attribute

Article type

Publication date

Search Results

7,819 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Lung Non-Small Cell Carcinoma"
Page 1
The biology and management of non-small cell lung cancer.
Herbst RS, Morgensztern D, Boshoff C. Herbst RS, et al. Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. Nature. 2018. PMID: 29364287 Review.
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and mult …
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past t …
Early palliative care for patients with metastatic non-small-cell lung cancer.
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Temel JS, et al. N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678. N Engl J Med. 2010. PMID: 20818875 Free article. Clinical Trial.
BACKGROUND: Patients with metastatic non-small-cell lung cancer have a substantial symptom burden and may receive aggressive care at the end of life. We examined the effect of introducing palliative care early after diagnosis on patient-reported …
BACKGROUND: Patients with metastatic non-small-cell lung cancer have a substantial symptom burden and may …
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.
NSCLC Meta-analysis Collaborative Group. NSCLC Meta-analysis Collaborative Group. Lancet. 2014 May 3;383(9928):1561-71. doi: 10.1016/S0140-6736(13)62159-5. Epub 2014 Feb 25. Lancet. 2014. PMID: 24576776 Free PMC article. Review.
BACKGROUND: Individual participant data meta-analyses of postoperative chemotherapy have shown improved survival for patients with non-small-cell lung cancer (NSCLC). We aimed to do a systematic review and individual participant data meta-analysis to e …
BACKGROUND: Individual participant data meta-analyses of postoperative chemotherapy have shown improved survival for patients with non …
Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y. Chen R, et al. J Hematol Oncol. 2020 May 24;13(1):58. doi: 10.1186/s13045-020-00881-7. J Hematol Oncol. 2020. PMID: 32448366 Free PMC article. Review.
Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. ...In this review, we summarize the recent advances in advanced/metastatic NSCLC therapeutics with a specific foc …
Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis …
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Ettinger DS, et al. J Natl Compr Canc Netw. 2017 Apr;15(4):504-535. doi: 10.6004/jnccn.2017.0050. J Natl Compr Canc Netw. 2017. PMID: 28404761
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. ...
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and …
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Yu HA, Yang JC, Hayashi H, Goto Y, Felip E, Reck M, Vigliotti M, Dong Q, Cantero F, Fan PD, Kanai M, Sternberg DW, Jänne PA. Yu HA, et al. Future Oncol. 2023 Jun;19(19):1319-1329. doi: 10.2217/fon-2022-1250. Epub 2023 May 22. Future Oncol. 2023. PMID: 37212796 Free article.
This article describes a clinical trial of a new drug to treat non-small-cell lung cancer. About a third of patients with non-small-cell lung cancer have tumors with changes (mutations) in a gene called EGFR, w …
This article describes a clinical trial of a new drug to treat non-small-cell lung cancer. About a …
Radiation and immunotherapy combinations in non-small cell lung cancer.
Azghadi S, Daly ME. Azghadi S, et al. Cancer Treat Res Commun. 2021;26:100298. doi: 10.1016/j.ctarc.2020.100298. Epub 2020 Dec 26. Cancer Treat Res Commun. 2021. PMID: 33387868 Free article. Review.
Non-small cell lung cancer (NSCLC) is a common and lethal malignancy. ...We review current evidence for synergy between radiation and immunotherapy in metastatic, locally advanced, and localized NSCLC and discuss ongoing studies....
Non-small cell lung cancer (NSCLC) is a common and lethal malignancy. ...We review current evidence for synergy …
Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer-A Stimulating Partnership.
Dams RV, Yuan Y, Robinson CG, Lee P. Dams RV, et al. Semin Respir Crit Care Med. 2020 Jun;41(3):360-368. doi: 10.1055/s-0039-3399578. Epub 2020 May 25. Semin Respir Crit Care Med. 2020. PMID: 32450590 Review.
Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer and the leading cause of cancer-related death. ...Notably, post-hoc analyses and early clinical trials provide a growing body of evidence to support a synergisti …
Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer and the leading cause of can …
Brigatinib: First Global Approval.
Markham A. Markham A. Drugs. 2017 Jul;77(10):1131-1135. doi: 10.1007/s40265-017-0776-3. Drugs. 2017. PMID: 28597393 Review.
Brigatinib (ALUNBRIG) is a small molecule antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company). In April 2017 brigatinib received accelerated approval in the USA for …
Brigatinib (ALUNBRIG) is a small molecule antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmace …
Osimertinib: First Global Approval.
Greig SL. Greig SL. Drugs. 2016 Feb;76(2):263-73. doi: 10.1007/s40265-015-0533-4. Drugs. 2016. PMID: 26729184 Review.
Osimertinib (Tagrisso(), AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC). Osimertinib ha …
Osimertinib (Tagrisso(), AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is …
7,819 results